Detection of urinary drug metabolite (Xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy by Holmes, E et al.
Detection of Urinary Drug Metabolite (Xenometabolome) Signatures in 
Molecular Epidemiology Studies via Statistical Total Correlation 
(NMR) Spectroscopy. 
 
Elaine Holmes1¥, Ruey Leng Loo1¥, Olivier Cloarec1, Muireann Coen1, 
Huiru Tang2, Elaine Maibaum1, Stephen Bruce1, Queenie Chan3, Paul 
Elliott3, Jeremiah Stamler4, Ian D. Wilson5, John C. Lindon1 and Jeremy K. 
Nicholson*1. 
 
1Biomolecular Medicine, Division of Surgery, Oncology, Reproductive 
Biology and Anaesthetics (SORA), Faculty of Medicine, Imperial College 
London, SW7 2AZ, UK  
2State Key Laboratory of Magnetic Resonance and Molecular and Atomic 
Physics, Wuhan Magnetic Resonance Centre, Wuhan Institute of Physics 
and Mathematics, The Chinese Academy of Sciences, Wuhan, 430071, PR 
China 
3Department of Epidemiology and Public Health, Imperial College London, 
St Mary's Campus, London, UK 
4Department of Preventive Medicine, Feinberg School of Medicine, 
Northwestern University, Chicago, IL, USA 
5Astra Zeneca, Department of Drug Metabolism and Pharmacokinetics, 
Macclesfield, UK 
*To whom correspondence should be addressed.  Email: 
j.nicholson@imperial.ac.uk
¥These authors contributed equally to this work 
 
 
 1
Key words: Drug metabolism, metabolic profiling, NMR spectroscopy, 
statistical total correlation spectroscopy (STOCSY), xenometabolome, 
population study, acetaminophen, ibuprofen, molecular epidemiology. 
 
Abbreviations: Confidence Interval (CI), Nuclear Magnetic Resonance 
(NMR), Statistical TOtal Correlation SpectroscopY (STOCSY), Orthogonal 
Projection to Latent Structure Discriminant Analysis (OPLS-DA), Principal 
Component Analysis (PCA), Statistical HeterospectroscopY (SHY), TOtal 
Correlation SpectroscopY (TOCSY), 1H-13C Heteronuclear Multiple Bond 
Correlation (HMBC), 1H-13C Heteronuclear Single-Quantum Correlation 
(HSQC), acetaminophen (A), acetaminophen glucuronide (AG), 
acetaminophen sulfate (AS), N-acetyl-cysteine acetaminophen conjugate 
(NAC), ibuprofen (IBU), 2-hydroxy ibuprofen (M1), 1-hydroxy ibuprofen 
(M2), 3-hydroxy ibuprofen (M3), carboxyibuprofen (M4), ibuprofen 
glucuronide conjugate (M5), 2-hydroxy ibuprofen glucuronide conjugate 
(M6), carboxyibuprofen glucuronide conjugate (M7), 3-hydroxy ibuprofen 
glucuronide conjugate (M8), 1-hydroxy ibuprofen glucuronide conjugate 
(M9). 
 2
Abstract 
Western populations use prescription and non-prescription drugs 
extensively, but large scale population usage is rarely assessed objectively in 
epidemiological studies. Here we apply statistical methods to characterize 
structural pathway connectivities of metabolites of commonly used drugs 
detected routinely in 1H NMR spectra of urine in a human population study. 
1H NMR spectra were measured for two groups of urine samples obtained 
from U.S.A participants in a known population study.  A total of 413 out of 
4290 samples contained acetaminophen as determined by the presence of 
acetaminophen resonances in the NMR spectrum. A correlation matrix was 
calculated for each selected acetaminophen metabolite resonance and the 
results were back-scaled to the mean centred data, in order to preserve the 
original structure of the spectral data facilitating interpretation. This 
approach effectively enabled rapid identification of the major and certain 
minor drug metabolites in common use in the population.  The xenobiotic 
metabolite profiles we detect on a large scale that are characteristic of 
population exposure we term the xenometabolome. It also enhanced the 
spectral contribution from signals correlated with the xenobiotic as distinct 
from resonances from endogenous molecules. The method was further 
exemplified for ibuprofen.  This work shows that statistical connectivities 
between drug metabolites can be established in routine ‘high throughput’ 
NMR screening of human samples from participants who have randomly 
self-administered drugs.  This approach should be of value in considering 
inter-population patterns of drug metabolism in epidemiological and 
pharmacogenetic studies.  
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Introduction 
 
The application of modern analytical and ‘omics’ technologies to study large 
scale population-based biological sample collections offers new 
opportunities to investigate many aspects of human biology and population 
phenotyping that were not envisaged at the time such epidemiological 
studies were initiated [1]. Systems biology tools, such as metabonomics, can 
provide a suitable analytical platform for studying the varied responses of 
individuals and populations to drug therapy; this falls within the domain of 
“molecular epidemiology” [1]. For the majority of these epidemiological 
studies, intake of nutrients and other xenobiotics is self-reported via 
questionnaires, and almost never controlled. Thus, the researcher is 
ultimately reliant upon the cooperation and recall by study participants to 
obtain important environmental data. Detecting and monitoring drug intake 
and metabolism in such epidemiological studies can be particularly 
problematic since many over the counter analgesics contain a mixture of 
pharmaceutical components, of which the participant may be unaware. 
Furthermore, not only can these compounds and their major and minor 
metabolites be detected with modern analytical technologies used for 
phenotyping, but treatment with these compounds can impact directly on the 
endogenous metabolic profile via pharmacological interactions. We define 
the new concept of the Xenometabolome as the multivariate description of 
the xenobiotic (foreign compound) metabolite profile of an individual or 
sample from an individual that has been exposed through any route (either 
deliberately or accidentally) to drugs, environmental pollutants or to dietary 
components that cannot be completely catabolized by endogenous metabolic 
enzyme systems. Thus for a population of individuals the xenometabolome 
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becomes an exogenous part (not under mammalian genomic control) of the 
metabolic phenotype (metabotype) of that group that is characteristic of their 
general environmental exposures to chemicals or their behavioural choices 
relating to drug use. The ability to monitor exposure to xenobiotics, which 
may not be toxic in their own right, but which may carry a risk to certain 
individuals in populations after long term exposure, is an important in the 
broad context of epidemiological risk assessment and allows connection 
between ‘real world’ analytical data and epidemiological factors.  Recently 
we have applied NMR spectral tools to the investigation of biochemical 
features of the urine samples collected as part of the INTERSALT and 
INTERMAP Studies [2, 3], which investigate the role of nutrition in adverse 
population blood pressure levels [4-9]. These samples were obtained from 
many populations and carry unique biochemical information about those 
groups and individuals [4-9]. 
 
Ongoing work on animal and human metabolic phenotyping [10-12] has 
revealed characteristic metabolic signatures relating to specific genotypes 
and strains of animal. These metabotypes are also heavily influenced by diet 
[10] and gut microfloral contributions [13, 14]. In addition to metabolic 
phenotyping, we and others have previously shown that NMR spectroscopy 
is an effective tool for profiling the broad metabolic composition of 
biological samples [15, 16] and can also be applied as a discovery tool in 
drug metabolism studies [17, 18]. NMR profiling approaches and techniques 
that disperse overlapping signals such as 2-dimensional NMR spectroscopic 
experiments and partial purification using chromatographic methods have 
been extensively applied to aid the isolation and identification of xenobiotics 
[19, 20].  Alternative approaches to detecting drug metabolites in biological 
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samples include mass spectrometric methods such as searching for specific 
drug metabolite fragment patterns [21, 22] and chromatographic assays [23, 
24]. LC-NMR and LC-MS-NMR approaches have proved particularly 
effective metabolic probes [25-27].   
 
Combining the capacity of NMR spectroscopy to simultaneously profile 
endogenous metabolites relating to specific phenotypes, and also to provide 
information on the intake and metabolism of xenobiotics such as drugs, we 
have used a new metabonomic approach to probe the detection of major 
urinary metabolites of xenobiotics in population studies. We and others have 
shown the power of pattern recognition tools for studying the metabolic 
effects of toxins and drugs [28-30] and the use of “statistical spectroscopic” 
methods for biomarker recovery and molecular structure assignment. In 
particular, orthogonal projection to latent structure discriminant analysis 
(OPLS-DA) [31], statistical total correlation spectroscopy (STOCSY) [32] 
and statistical heterospectroscopy (SHY) [33] have proven useful for 
improved detection of potential biomarkers and for removing confounding 
analytical or biological variation from datasets. Since these methods operate 
using full NMR spectral resolution (digital point space), they allow direct 
identification of metabolites from the mathematical models via spectral 
reconstruction.  
 
Here we present a strategy for directly detecting drugs and their metabolites 
in the biofluids of individuals sampled from free living human populations; 
this method is based on statistical correlation matrices calculated for 
individual spectral data points. Acetaminophen [34] and ibuprofen [35] are 
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used to exemplify this method based on extensive knowledge of their 
metabolism and their popularity as over-the-counter analgesics.   
 
Methods 
 
Study design. Urine samples from free living humans and corresponding 
information on analgesic intake were sourced from the INTERMAP Study 
[36]. Methods of data collection have been described [4]. Each individual 
attended a specified clinic centre on four occasions; the first 2 and last 2 
visits were on adjacent days with a period of 3-6 weeks between these pairs 
of visits. Data collection included blood pressure on 8 occasions (2 per visit), 
four in depth 24h dietary recalls,  two 7-day daily alcohol assessments by 
interview, and  extensive questionnaire data on medication (including 
analgesic use), smoking, and other variables.  At the first and third visits, a 
timed 24 hour urinary collection was initiated, which was completed the 
following day in the clinic, according to a standardized protocol. Boric acid 
preservative (approximately 5g/L) was incorporated in the urine collections.  
Specimens were mixed thoroughly and total volume recorded. Aliquots (9 
ml) were taken, frozen at -20ºC within 24 hours, and shipped frozen to the 
central laboratory in Leuven, Belgium. The samples were stored at -40 ºC 
before shipment on dry ice to the metabonomic laboratory at Imperial 
College. For this study, two subsets of samples were selected from 4290 
urine spectra (first and repeat clinic visits for 2145 U.S.A. participants) 
based on the presence or absence of acetaminophen.    A subset of 70 
samples was selected from 413 urine spectra containing acetaminophen.  A 
further subset of spectra was selected from the remaining 3877 urine spectra 
which did not contain acetaminophen metabolites. A subset of 70 samples 
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(for consistency in comparison with the acetaminophen dataset) was selected 
from 353 urine spectra containing ibuprofen and its metabolites and a further 
subset of 70 spectra were selected as control using the remaining 3937 
spectra.   
 
Preparation of samples for 1H NMR spectroscopy. Urine samples stored at -
40oC were thawed completely before mixing 500 μL of the sample with 250 
μL of phosphate buffer for stabilisation of the urinary pH 7.4 (± 0.5), and 75 
μL of sodium 3-trimethylsilyl-(2,2,3,3-2H4)-1-propionate (TSP) in D2O (final 
concentration 0.1mg/mL) solution for internal calibration at δ 0.0.  The D2O 
provided an NMR lock signal for the NMR spectrometer. Each sample was 
placed into a 96-well plate for analysis and the remaining sample refrozen. 
Samples were mixed and the 96-well plate was left to stand for 10 minutes 
before centrifuging at 4,000 rpm for 10 minutes to remove any precipitate 
from the sampling volume.  
 
1H-NMR spectroscopic analysis of urine samples. Conventional 1H-NMR 
spectra of the urine sample were obtained using a Bruker (Bruker Biospin, 
Rheinstetten, Germany) Avance 600 spectrometer operating at 600.29 MHz 
in flow-injection mode. Samples were automatically delivered to the 
spectrometer using a Gilson 215 robot incorporated into the BEST (Bruker 
Efficient Sample Transfer) system. The one-dimensional 1H NMR spectra of 
urine were acquired using a standard one-dimensional pulse sequence 
NOSEYPR1D (recycle delay-90°-t1-90°-tm-90°-acquisition; XWIN-NMR 
3.5) with water pre-saturation during both the recycle delay (2 s) and mixing 
time (tm, 150 ms)  (See Supp 1 for all NMR acquisition parameters). The 90° 
pulse length was adjusted to ~10 µs and t1 was set to 3 µs, providing an 
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acquisition time of 2.73 s and a total pulse repetition time of 4.88 s. For each 
sample, 64 free induction decays (FIDs) were collected into 32K data points 
using a spectral width of 20 ppm. The FIDs were multiplied by an 
exponential weighting function corresponding to a line broadening of 0.3 Hz 
and data were zero-filled to 64k data points prior to Fourier transformation 
(FT). 
 
2-Dimensional NMR analyses were performed on selected samples for 
identification of drug metabolites. 1H-1H TOtal Correlation SpectroscopY 
(TOCSY), 1H-13C Heteronuclear Multiple Bond Correlation (HMBC) and 
1H-13C Heteronuclear Single-Quantum Correlation (HSQC) 2D NMR 
spectra were acquired on two urine samples containing typical levels of 
acetaminophen metabolites and another urine sample containing ibuprofen 
metabolites.  For the 2D TOCSY spectra of urine were acquired using an 
mlevphpr pulse sequence (XWIN-NMR 3.5) where 56 transients per 
increment and 120 increments were collected into 2K data points over a 
spectral width of 10.5ppm in both dimensions using the MLEV17 spin-lock 
scheme with a spin-lock power of 6 kHz. A recycle delay of 1.2 s was used, 
during which water presaturation pulse was switched on. The total 
measurement time per sample was approximately 3 hours. 
 
1H-13C HMBC (hmbcgplpndqfpr, XWIN-NMR 3.5) and HSQC (hsqcetgppr, 
XWIN-NMR 3.5) spectra were acquired at 600 MHz for 1H and 150 MHz 
for 13C with the spectral width of 10.5 ppm for 1H and 220 ppm for 13C.  
Experimental parameters for HSQC were: 100 increments, 280 transients, 2k 
data points in the 1H detection dimension. The experimental parameters for 
1H-13C HMBC were: 100 increments, 416 transients, 2k data points in the 1H 
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detection dimension. For processing, TOCSY and HSQC data were apodized 
using shifted sine-bell; HMBC spectra were processed using sine-bell 
weighting in both dimensions.  All data were zero-filled to 2k data points in 
both dimensions prior to FT.  The total measurement time was 
approximately 6 hours and 18 hours per sample for HSQC and HMBC 
respectively. 
 
1H-NMR spectral processing and multivariate analysis. Baseline correction 
and phasing of the spectra were achieved with in-house software (T. Ebbels 
and H. Keun).  All spectra were referenced to TSP automatically using an in-
house routine written in MATLAB® 7.0.1 (MathWorks, Natick, MA) and 
each spectrum was collected into 18001 data points with a data point 
resolution of 0.0005 ppm prior to data analysis. The regions of the spectra 
containing the water (δ 4.7-4.9) and urea (δ 5.6-6.0) resonances were 
removed to eliminate both the variation in water suppression and the 
variation in the integral of the urea signal due to partial cross-saturation via 
the solvent exchanging protons. The remaining data (n = 16599) point 
intensities were normalised to the sum of the row (total spectrum) prior to 
further data analysis. 
 
Multivariate analysis and experimental design. 
OPLS-DA analysis.  A Principal Component Analysis (PCA) model was 
constructed for a subset of INTERMAP participants from the U.S.A. in order 
to identify a subset of urine specimens from participants who had ingested 
acetaminophen and those who had not. To optimize visualization of drug 
resonances from spectra exhibiting high degree biochemical variation, a 
projection to latent structure algorithm with an inbuilt orthogonal filter 
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(OPLS-DA) [31, 37] was then applied to spectra which were randomly 
selected from the two subsets of the data that were identified from the PCA 
model, comprising a group who had spectral evidence of acetaminophen 
intake (n=70) and a control group of non-users (n=70).  The variation 
common to the class variable matrix Y (i.e. consumer / non consumer of 
acetaminophen), can be observed from the R2Y, and the class validity of the 
OPLS-DA model was tested against over-fitting using the cross-validation 
parameter, Q2Y.   
The analysis was repeated for a subset of INTERMAP participants whose 
urine spectra contained evidence of ibuprofen ingestion and a second group 
of randomly sampled control samples.   
 
Statistical total correlation spectroscopy (STOCSY): STOCSY was 
performed on the subset of samples from acetaminophen users. Correlation 
matrices were calculated for data points selected to coincide with the peak 
maxima of acetaminophen related NMR signals with a view to establishing 
correlations between the separate proton environments for each metabolite 
and generating molecular structural information. Because the NMR peak 
intensities of different peaks from the same molecule are directly related to 
the number of protons contributing to the signal, the relative intensity of 
signals from the same molecule should in theory be linear (r =1).  However, 
in reality the correlation between any two data points in a sample set will be 
somewhat weaker, depending on degree of overlap from other molecules 
contributing to the spectrum.   
Correlations between the selected resonance and all the other data points of 
the spectra are presented using colour coding (corresponding to the r2 =1 
instead of r) for ease of visualization.  Upward oriented data points reflect a 
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positive correlation to the selected resonance of interest, whereas downward 
oriented data points signify negative correlations.  The signal intensity and 
shape is used to represent the covariance matrix, which provides a graphical 
similarity to NMR spectra, thereby facilitating ease of interpretation by the 
NMR spectroscopist.  
The bootstrapped [38] correlation coefficients were computed on all samples 
containing acetaminophen metabolites.  The mean and the median of 
correlation coefficient between each pair of the selected data points, together 
with the 95% confidence interval for the sampled population, were 
computed.  The bootstrapped process, an iterative re-sampling method was 
applied using a randomly selected sample set containing the same number of 
samples as the original OPLS-DA model defining the differences between 
acetaminophen intakes, i.e. 70 from the 413 samples containing 
acetaminophen metabolites. Random selection of the sample set was 
repeated a thousand times in order to assess the probability of obtaining the 
significance of the OPLS-DA model by chance.  The bootstrapping process 
was repeated for all 353 samples containing ibuprofen and its metabolites. 
 
 
Results 
 
Acetaminophen metabolism. The metabolism of acetaminophen is well-
documented [34, 39];  major metabolites are shown in Figure 1. Resonances 
arising from the parent drug and many of its metabolites were observed in 
the 1D NMR urine spectra from participants who had not ingested any drug 
(Figure 2A) or had ingested either acetaminophen (Figure 2B-C) or 
ibuprofen (Figure 2D-E; as discussed below). Assignments were made from 
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literature values [40, 41] and from a series of 2-D NMR measurements on 
selected samples containing acetaminophen. 1H-1H (TOCSY) and 1H-13C 
(HSQC, HMBC) spectra are also illustrated for acetaminophen and its 
NMR-detected metabolites (Supp 2). Chemical shifts are provided for each 
of the reported metabolites (Table 1). 
 
The PCA model which based on all the 4290 urine spectra showed 413 
spectra containing acetaminophen and its metabolites as outliers, with the 
remaining 3877 urine spectra did not show acetaminophen metabolites.  
OPLS-DA analysis on a subset of 70 samples from the two groups 
(acetaminophen users or non users) generated a scores plot showing clear 
differentiation of the spectra based on acetaminophen intake of the 
participants (Figure 3). The OPLS-DA model calculated for the 
acetaminophen versus control groups generated one predictive component 
with 2 orthogonal components and explained 89% of the variance of on the 
class variable matrix (Y) with a predictive value of 72% according to the 
cross validation parameter (Q2Y =0.72).  The coefficients plot shows the 
differential contributions of spectral regions in contributing to discrimination 
between the two groups (acetaminophen ingestion vs. non-ingestion). The 
resonances exerting the strongest influence on the class discrimination relate 
to the acetaminophen parent compound, its glucuronide and sulfate 
conjugates, with a slightly weaker contribution from the N-acetyl cysteine 
conjugate (Figure 3A - 3C). The glucuronide conjugate was the dominant 
urinary excretion product of acetaminophen in all 413 cases with a mean 
ratio of 1:2.1 for sulfate:glucuronide. In addition, unchanged acetaminophen 
compound and its N-acetyl cysteine conjugate were also observed in the 
majority of the spectra but were present at much lower concentrations.   
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 Having modelled the spectral features characterizing acetaminophen 
ingestion, statistical correlation was performed for prominent acetaminophen 
related resonances to determine correlations between protons within the 
same molecule, and to ascertain the statistical relationship between 
resonances from the parent compound and resonances from acetaminophen 
metabolites.  Statistical correlations were computed on full resolution spectra 
for the 413 samples containing acetaminophen metabolites.  The correlation 
matrix derived from correlations between the data point corresponding to δ 
2.17, at the apex of the N-acetyl proton signal from acetaminophen 
glucuronide and all other data points, showed high correlation values with 
most of the other glucuronide metabolite resonances (Figure 4A – 4C and 
Supp 3).  This includes the pair of doublets in the aromatic region of the 
spectrum (δ 7.13, with a mean correlation coefficient, r= 0.84 and a 95% 
confidence interval (CI) of 0.79 – 0.88, and 7.36, r = 0.98; with 95% CI of 
0.97 – 0.99), the characteristic doublet at δ 5.10 (r = 0.95; with 95% CI of 
0.93 – 0.97) for the anomeric proton signal of the glucuronide ring and the 
signals from the glucuronide ring protons at δ 3.62 (r = 0.89; with 95% CI of 
0.85 – 0.93).  Correlation value between the N-acetyl δ 2.17 signal and 
signal at δ 3.89 derived from the protons H5′ on the glucuronide ring were 
somewhat weaker (r = 0.72; 95% CI of 0.61 – 0.82).  These weaker 
correlation values were influenced by partial overlap of signals from small 
amounts of glucose.   
In addition, the N-acetyl peak for the glucuronide was highly correlated with 
the N-acetyl peak for the sulfate at δ 2.18 (r = 0.81; 95% CI of 0.74 – 0.87), 
N-acetyl-cysteine at δ 2.15 (r = 0.82; 95% CI of 0.77 – 0.87) and parent drug 
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molecule at δ 2.16 (r = 0.87; 95% CI of 0.82 – 0.91).  Positive correlations 
were also observed between the N-acetyl of the glucuronide conjugate and 
the aromatic protons of the sulfate conjugate at δ 7.31 and 7.46 (r = 0.76; 
95% CI of 0.66 – 0.83 and 0.90; 95% CI of 0.85 – 0.93 respectively). The 
correlation value between the N-acetyl peak for the glucuronide conjugate 
and the N-acetyl cysteine at δ 1.86 (r = 0.61; 95% CI of 0.5 – 0.72) or the 
aromatic proton of the N-acetyl cysteine (H3) at δ 6.96 (r = 0.63; 95% CI of 
0.53 – 0.73) was somewhat weaker when compared to the correlation 
between the glucuronide conjugate and the N-acetyl cysteine resonance at δ 
2.15 (r = 0.82; 95% CI of 0.77 – 0.87).  The difference in correlation values 
for the two N-acetyl cysteine resonances at δ 2.15 and δ 1.86 or δ 6.96 with 
the N-acetyl glucuronide peak was most likely caused by overlap of the N-
acetyl cysteine resonance at δ 2.15 with the N-acetyl signal from 
acetaminophen itself.   
The schematic diagram in Figure 5 compares the molecular structural 
information obtained by TOCSY, HSQC, HMBC and STOCSY analyses 
respectively for acetaminophen glucuronide. Many of the correlations 
observed by the statistical correlation method, for example between the N-
acetyl proton and the aromatic protons, can not be observed by the NMR 
pulse sequence experiments. Thus, the STOCSY method in this case was 
able to provide ‘constitutional’ correlation / connectivity for all nuclei which 
are present in a given molecule, regardless of the number or the existence of 
covalent chemical bonds or the magnetization transfer between the nuclei.  
This statistical correlation procedure is also potentially more efficient than 
2D measurements, in some circumstances. For example, in that the analysis 
time taken to acquire this dataset (n=413) for the statistical correlation 
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analysis was approximately 56 hrs (8mins x 413 samples) and encompassed 
all samples. In contrast the series of 2D NMR spectra took a total of 27 hrs 
to acquire for a single sample, which would not necessarily be a 
representative sample for all metabolites profiled. 
The correlation matrix for the acetaminophen sulfate conjugate was 
calculated at the apex corresponding to the proton from the aromatic ring at 
δ 7.46 as this peak was deemed to be the least overlapped of the 
acetaminophen sulfate resonances.  A high correlation was demonstrated 
between this resonance and all the other resonances of the sulfate conjugate, 
e.g., with the doublet derived from the aromatic proton at δ 7.31 (r = 0.9; 
95% CI of 0.86 – 0.93) and with the singlet derived from the methyl of the 
acetyl at δ 2.18 (r = 0.94; 95% CI of 0.91 – 0.96) (Table 2).  
 
Ibuprofen metabolites. The principal component 1 and principal component 
7 of the PCA model of the total data set, after excluding strong outliers due 
to the presence of high concentrations of glucose or acetaminophen, showed 
a further 353 samples as outliers due to the presence of ibuprofen 
metabolites.  To exemplify the methodology further, OPLS-DA analysis was 
performed on the second data set of samples.  A subset of 70 samples was 
selected randomly from participants who had taken ibuprofen compared with 
a control group. As with acetaminophen, the metabolism of ibuprofen is well 
documented [35, 42] (Figure 6) and produces distinctive resonances in the 
1H NMR urine spectrum (Figure 2D). Participants who had ingested 
ibuprofen were clearly differentiated from controls as visualized in the 
OPLS-DA scores and coefficients plots (Figure 7).  The OPLS-DA model, 
which used one predictive component and one orthogonal component 
explained 54% of the variance within Y matrix (R2Y=0.54) with a predictive 
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value of 49% according to the cross validation parameter (Q2Y =0.49).  
Similarly, correlation matrices calculated for each of the data points at the 
apex of an ibuprofen related signal showed strong correlation between 
signals derived from protons on the same molecule and to a lesser extent 
from signals from other ibuprofen related molecules. The correlation 
coefficients calculated from the data point corresponding to δ 1.21, at the 
apex of the methyl groups of the isobutyl side chain of 2-hydroxyibuprofen 
(Figure 6, Hc/Hd position for M1) and its glucuronide conjugate (M6) are 
shown in Figure 8. High correlations values were observed between this data 
point and those corresponding to the methyl groups (δ 1.52; r = 0.94; 95% 
CI of 0.92 – 0.97) and the aromatic protons (around δ 7.24; r = 0.94; 95% CI 
of 0.92 – 0.9) of both metabolites. The –CH2 resonance of 2-
hydroxyibuprofen (M1) at δ 2.79 (r = 0.96; 95% CI of 0.94 – 0.97) and the –
CH2 resonance of 2-hydroxyibuprofen glucuronide conjugate (M6) at δ 2.80 
(r = 0.92; 95% CI of 0.9 – 0.94) were also strongly correlated with the δ 1.21 
methyl signal (Figure 8).  Additionally, STOCSY driven from the apex of 
the resonance at δ 1.21 also highlighted correlations between 2-
hydroxyibuprofen and some of the other dominant ibuprofen metabolites, 
e.g. the carboxy-ibuprofen (Figure 6, M4) and its glucuronide conjugate 
(M7).  For example, strong correlation values describing the relationship 
between the 2-hydroxyibuprofen methyl at δ 1.21 and resonances of the 
carboxy-ibuprofen were found; CH3 (δ 1.40 , r = 0.97; 95% CI of 0.95 – 
0.98), the –CH group (δ 2.61, r = 0.88; 95% CI of 0.85 – 0.91) and the 
methyl group from the propionic acid side chain (δ 1.07, r = 0.87; 95% CI of 
0.92 – 0.9).  Strong correlation was also observed between the 2-
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hydroxyibuprofen methyl and the anomeric proton from the ibuprofen 
glucuronides resonance at δ 5.56 (, r = 0.92; 95% CI of 0.88 – 0.95).   
 
Discussion  
Understanding the patterns of use and differential metabolism of drugs in 
populations would provide important background genetic (drug metabolizing 
enzymes) and social information in epidemiological studies designed to 
understand the demographics of human disease.  The concept of the 
xenometabolome is useful as it provides potential metrics of population drug 
(and even environmental pollutant) exposure in an epidemiological context.  
In the majority of such epidemiological studies, this information is difficult 
or impossible to derive – but the recent advent of spectroscopy based 
population phenotyping methods coupled with statistical information 
recovery tools provides the possibility for the first time as illustrated here for 
the widely used drugs acetaminophen and ibuprofen. The combined 
application of OPLS-DA and statistical correlation (STOCSY) to 1D NMR 
urine spectra from a human population study enabled discrimination of 
samples based on analgesic intake and allowed structural characterization of 
the analgesics and their metabolites. Strong statistical correlations between 
signals deriving from protons on the same molecule but in different chemical 
environments were observed in most cases, as demonstrated for the 
glucuronide and sulfate conjugates of acetaminophen and the 2-hydroxy, 
carboxyl and glucuronide conjugates of ibuprofen (Figures 3 and 7).  Where 
a drug metabolite was present in low concentrations and prone to overlap 
with resonances from other endogenous or exogenous molecules, for 
example the N-acetyl cysteine conjugate of acetaminophen, correlations 
obtained between discrete proton signals on the same molecule were lower, 
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but nevertheless detectable. In contrast to conventional 2-dimensional NMR 
pulse sequences, which are most efficient at identifying cross peaks or 
correlations between proton groups in close physical proximity, the 
statistical correlation method detects covariance of resonances and is, 
therefore, not influenced by distances in terms of bond length. For example, 
from the 2-dimensional 1H-1H TOCSY spectrum, it was possible to identify 
coupling between the H2/H3 and H1′/H2′/H3′/H4′/H5′ moieties of 
acetaminophen glucuronide (Figure 5). However, unlike the STOCSY 
spectrum, no cross-peak or correlation between the N-acetyl (Ha) and 
aromatic protons (H2/H3 and H1′/H2′/H3′/H4′/H5′) on the acetaminophen 
glucuronide molecule proton groups could be observed as these are 
separated by 5 and 8 bond (lengths) respectively for H3 and H1′. In addition, 
an obvious advantage of the mathematical correlation method over 2-D 
NMR spectroscopy is the time required to generate structural information for 
the metabolites.  Each 1-D NMR spectrum is generated in 8 minutes, 
whereas a typical 2-D TOCSY requires approximately 3 hrs of acquisition 
time, and an HMBC up to 18 hrs, to obtain an adequate signal to noise ratio.  
Therefore, the collation of rapidly acquired 1-D spectra can offer a more 
efficient solution to analyzing drug metabolism in human populations since 
the use of STOCSY often negates the requirement for performing extensive 
2D NMR experiments and is therefore more time efficient.  
 
Although back-scaling the unit-variance scaled correlation values to the 
covariance matrix restores much of the original spectral structure, the 
weighting afforded to highly correlated signals results in an emphasis on the 
drug metabolites producing a down-weighting or flattening of signal 
contributions from non-correlated molecules, in this case the majority of the 
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endogenous molecules.  This has the effect of simplifying the interpretation 
of the correlated structures for the molecule of interest, as is apparent in the 
correlation spectra where the glucuronide ring resonances at δ 3.62 and 3.89 
are clearly visible. These signals are often difficult to assign in a standard 1D 
1H NMR spectrum due to overlapping resonances from glucose, CH groups 
of amino and organic acids, and other sugar moieties.  
 
Most importantly, the STOCSY application provides structural information 
not just pertaining to protons on the same molecule, but also connects 
signals for protons deriving from closely related molecules. For example, 
metabolites derived from the same parent compound, e.g., acetaminophen, 
acetaminophen glucuronide, acetaminophen sulfate and N-acetyl cysteine 
acetaminophen all show correlations which vary in strength according to the 
degree of overlap with other endogenous or exogenous signals. This may 
prove a particularly useful feature in cases where the metabolism of a 
xenobiotic is not well characterized, and may help to differentiate xenobiotic 
metabolites from drug-induced changes in endogenous molecules.  STOCSY 
can differentiate between endogenous and exogenous signals based on the 
structure of the pharmacological connections. The negative correlation 
matrix driven from any drug metabolite resonance will contain only 
endogenous responses to the drug since drug metabolites should show a 
positive correlation. The positive correlation matrix will indicate either drug-
related or endogenous correlations with drug metabolites. However, one 
would expect that in most cases the correlations between drug metabolites 
would be stronger than correlations observed between drug metabolites and 
endogenous molecules. In the case of the positive correlation matrix, 
differentiation can be made on the basis of molecular structural information, 
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since endogenous molecular structures will be largely implausible for drug 
bio-transformations.  It is also possible to draw inferences regarding the 
strength of inter-molecular correlations. The correlation between 
acetaminophen and its sulfate conjugate is weaker than the correlation 
between the acetaminophen parent and the glucuronide. Factors that may 
influence drug metabolite ratios include saturation of metabolic pathways, 
interaction with other pharmaceuticals, nutritional status and time of 
administration of the drug in relation to sampling time. For example, 
acetaminophen sulfate is known to have a longer half life (approximately 3.5 
hours) than acetaminophen glucuronide (approximately 2 hours) and the 
capacity for sulfation is more readily saturated [43].  
 
In addition to applying the STOCSY method in conjunction with projection 
methods for detection and structural identification of drug metabolites in 
human biofluid samples, correlation between drugs and endogenous 
metabolites can also be visualized. Metabolic effects of over the counter 
therapeutics can impact on disease risk or development. For example, heavy 
or prolonged use of analgesics such as aspirin or phenacetin has been 
implicated in the development of renal papillary necrosis and associated end 
stage renal failure [44-46]. It is therefore important to understand variation 
in the metabolism of these xenobiotics both at the individual and at the 
population level. 
 
In summary, the combination of NMR spectroscopic profiling of biological 
fluids with the STOCSY method for identification of correlated signals 
confers molecular structure elucidation potential both for xenobiotics and 
endogenous molecules. It can be a powerful tool for the identification of 
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candidate biomarkers generated from metabonomic studies. Detection and 
identification of drug metabolites in urine or plasma can be used to verify 
questionnaire data in human clinical studies and may also be useful for 
exploring idiosyncratic responses to drugs. Measurement of major 
xenometabolome components, which can be performed as part of a general 
exploratory metabolic profiling procedure, is of value because it carries extra 
environmental chemical information that might be important in the 
assessment of overall disease risk profiles of populations and cannot be 
currently assessed using questionnaire data (performed as part of 
epidemiological studies) alone. Furthermore, correlations between drug 
metabolites and molecules of endogenous origin may uncover important 
information on mechanisms of action and potential population exposure 
risks. This approach should be extendable to investigate differential 
metabolism of “self-dosed” individuals in populations of different ethnic / 
lifestyle backgrounds.  
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Figure Captions: 
Figure 1. Schematic showing the chemical structures of acetaminophen (A) 
and its metabolites. 
 
Figure 2: Typical 1H NMR spectra of urine from participants: A) no 
analgesic intake; B) after ingestion of acetaminophen; C) expansion on 
acetaminophen region at δ 2.16; D) after ingestion of ibuprofen; E) showing 
the characteristic of the anomeric proton signal of the ibuprofen glucuronide 
rings. For a key to the identity of ibuprofen metabolites, refer to Figure 6 
 
Figure 3. A) The OPLS-DA loading coefficient plot shows that the basis of 
differentiation between these two groups (acetaminophen ingestion versus 
controls) primarily results from the presence of acetaminophen (A), 
acetaminophen glucuronide (AG), acetaminophen sulfate (AS) and the N-
acetyl cysteine conjugate of acetaminophen (NAC) denoted by the red / 
orange colour of the resonances indicating a r2 > 0.5 in discriminating 
between the two groups. B) Expansion for the aromatic region showing 
signals for acetaminophen and its related metabolites C) Expansion on 
acetaminophen region at δ 2.16.  D) The O-PLS-DA scores plot showing 
discrimination between 2 classes (blue = control, red = participants who had 
taken acetaminophen). 
 
Figure 4. A) STOCSY plot derived from the correlation matrix calculated 
between the data point at the peak maxima of the N-acetyl proton signal of 
acetaminophen glucuronide (AG) resonance (δ 2.17) and all other data 
points, as indicated by the arrow, showing strong correlation (red/orange 
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data points) with resonances at δ 3.62, 3.89, 5.1, 7.13 and 7.36. Slightly 
weaker correlations with acetaminophen (A), and acetaminophen sulfate 
(AS).  B) Expansion for the aromatic region showing signals for 
acetaminophen and its related metabolites.  C) Expansions for the δ 2.17 N-
acetyl resonance of acetaminophen metabolites.  
 
Figure 5 Schematic for acetaminophen glucuronide comparing the intra-
molecular 1H-1H and 1H-13C correlations detected in the TOCSY (blue), 
HSQC (brown), HMBC (green), and the intra- and inter-molecular 
correlations given by STOCSY (red) analyses. Note that these are the actual 
observed, and not the theoretical correlations. Although the NMR 
parameters were optimised for this study by adjusting the acquisition / 
processing parameters, it may be possible to observe further correlation 
structures from each of these measurements. 
 
Figure 6. Schematic showing the chemical structures of ibuprofen and its 
major metabolites. 
 
Figure 7 A) OPLS-DA loading coefficient plot shows that the basis of 
differentiation between these two groups (ibuprofen users and non users) 
primarily results from the presence of 2-hydroxy, carboxyl and glucuronide 
conjugates of ibuprofen;  B) The OPLS-DA scores plot showing 
discrimination between 2 classes (blue = control, red = participants who had 
consumed ibuprofen). 
 
Figure 8. A) STOCSY plot derived from the correlation matrix between all 
data points and the data point at the peak maxima relating to the combined 
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resonances from 2-hydroxy signal of ibuprofen and its glucuronide 
resonance (δ 1.21), as indicated by the arrow. Strong correlations 
(red/orange data points) between this resonance and many related ibuprofen 
resonances can be observed. B) Expansion for the aromatic region showing 
resonances for ibuprofen and its related metabolites.  C) Expansions for the 
δ 0.6 – 1.6 region showing resonances of ibuprofen metabolites.  (IBU = 
ibuprofen, M1 = 2-hydroxy ibuprofen, M2 = 1- hydroxyl ibuprofen, M3 = 3-
hydroxy ibuprofen, M4 = carboxyibuprofen, M5 = ibuprofen glucuronide, 
M6 = 2- hydroxyibuprofen glucuronide conjugate, M7 = carboxyibuprofen 
glucuronide conjugate, M8 = 3=hydroxyl iburprofen glucuronide conjugate 
and M9 = 1 –hydroxy ibuprofen glucuronide conjugate).  
 
Supplement 1: Spectrometer acquisition parameters for standard 1D 
(NOSEYPR1D), TOCSY, HSQC and HMBC 
 
Supplement 2: Selected 2D NMR spectra of urine from a participant after 
ingestion of acetaminophen: A) TOCSY spectrum; B) HSQC spectrum; C) 
HMBC spectrum; D) 1D spectrum. 
 
Supplement 3: Bootstrapped correlation coefficient showing the mean and 
median correlation coefficient (together with the 95% confidence interval) 
for 413 1H NMR spectra samples based on 1000 re-samplings with 
replacement. 
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Table 1: 1H and 13C NMR chemical shifts and coupling constants (J/Hz) for 
acetaminophen and its metabolites. 
 
Metabolites 1H 
shift 
(δ) 
Coupling 
constant 
(J/Hz) 
Appearancea Assignmentb 13C shift 
(δ)c
2.16 - s Ha 25.8 (Ca) 
6.91 8.8 d H3 120 (C3) 
Acetaminophen 
(A) 
7.25 8.8 d H2 128.2d 
(C2) 
2.17 - s Ha 25.8 (Ca) 
3.62 - m H2′,3′,4′ 75.4e 
(C2’/3’) 
78.8 (C4’)
3.89 8.9 d H5′ 76.5 (C1’)
5.10 6.8 d H1′ 103.4 
(C1’) 
7.13 8.8   d H3 120.3 
(C3) 
Acetaminophen 
glucuronide 
(AG) 
7.36 8.8 d H2 127.3 
(C2) 
2.18 - s Ha 25.8 (Ca) 
7.31 8.8 d H3 125.2 
(C3) 
Acetaminophen 
sulfate (AS) 
7.46 8.8 d H2 126.7 
(C2) 
1.86 - s Hc 176.2(Cd)N-acetyl-L-
cysteinyl 
(NAC) 
2.15 - s Ha 25.8 (Ca) 
a d = doublet; s = singlet; m = multiplet.  b These assignments were based on 
1H-1H TOCSY NMR.  c Assignments were based on 1H – 13C HSQC and 
HMBC NMR.  d Observed in only one of the sample.  e Two signals 
observed. 
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Supplement 1:  
 
Parameters for NOESYPR1D experiments (1Dimensional 1H NMR spectra with 
solvent suppression) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
======== CHANNEL f1 ======== 
NUC1                 1H 
P1                 7.75 μsec 
PL1                 1.00 dB 
PL9                55.00 dB 
SFO1         600.2928245 MHz 
 
F2 - Processing parameters 
SI                 65536 
SF           600.2199568 MHz 
WDW                  no 
SSB                    0 
LB                  0.3 Hz 
GB                     0.0 
PC                  1.00 
F2 - Acquisition Parameters 
PROBHD          5 mm FI 
PULPROG        noesypr1d 
TD                     32768 
SOLVENT        D2O 
NS                      64 
DS                      8 
SWH               12019.23 Hz 
FIDRES          0.366798 Hz 
AQ             1.3631988 sec 
RG                   228.1 
DW                83.2 μsec 
DE                  7.00 μsec 
TE                 300.0 K 
D1            2.00000000 sec 
D8            0.10000000 sec 
D11           0.03000000 sec 
d12           0.00002000 sec 
MCREST        0.00000000 sec 
MCWRK         0.01500000 sec 
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Parameters for TOCSY experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
======== CHANNEL f1 ======== 
NUC1                 1H 
P1                 10.65 μsec 
p5                 26.68 μsec 
P6                 40.00 μsec 
p7                 80.00 μsec 
P17              2500.00 μsec 
PL1                 0.00 dB 
PL9                54.00 dB 
PL10               12.00 dB 
SFO1         600.2928250 MHz 
 
F1 - Acquisition parameters 
ND0                    1 
TD                   120 
SFO1            600.2928 MHz 
FIDRES         52.526527 Hz 
SW                10.500 ppm 
FnMODE             TPPI 
 
F2 - Processing parameters 
SI                  2048 
SF           600.2899643 MHz 
WDW                 SINE 
SSB                    2 
LB                  0.00 Hz 
GB                     0 
PC                  1.00 
 
F1 - Processing parameters 
SI                  2048 
MC2                 TPPI 
SF           600.2899657 MHz 
WDW                 SINE 
SSB                    2 
LB                 0.00 Hz 
GB                     0 
F2 - Acquisition Parameters 
PROBHD    5 mm TXI 1H-13 
PULPROG         mlevphpr 
TD                  2048 
SOLVENT           D2O 
NS                    56 
DS                     8 
SWH             6313.131 Hz 
FIDRES          3.082584 Hz 
AQ             0.1622516 sec 
RG                 228.1 
DW                79.200 μsec 
DE                  6.50 μsec 
TE                 300.0 K 
d0            0.00006855 sec 
D1            1.20000005 sec 
D9            0.09500000 sec 
d11           0.03000000 sec 
d12           0.00002000 sec 
d13           0.00000400 sec 
FACTOR1            6 
IN0           0.00015865 sec 
l1                    36 
MCREST        0.00000000 sec 
MCWRK         0.01500000 sec 
SCALEF               6 
 
 39
Parameters for HSQC experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
====== GRADIENT CHANNEL ===== 
GPNAM1         SINE.100 
GPNAM2          SINE.100 
GPX1                0.00 % 
GPX2                0.00 % 
GPY1                0.00 % 
GPY2                0.00 % 
GPZ1               80.00 % 
GPZ2               20.10 % 
P16              1500.00 usec 
 
F1 - Acquisition parameters 
ND0                    2 
TD                   100 
SFO1            150.9573 MHz 
FIDRES        301.886780 Hz 
SW               199.982 ppm 
FnMODE     Echo-Antiecho 
 
F2 - Processing parameters 
SI                  2048 
SF           600.2899613 MHz 
WDW                QSINE 
SSB                    2 
LB                  0.00 Hz 
GB                     0 
PC                  1.40 
 
F1 - Processing parameters 
SI                  2048 
MC2        echo-antiecho 
SF           150.9430146 MHz 
WDW                QSINE 
SSB                    2 
LB                  0.00 Hz 
GB                     0 
F2 - Acquisition Parameters 
PROBHD    5 mm TXI 1H-13 
PULPROG       hsqcetgppr 
TD                  2048 
SOLVENT           D2O 
NS                   280 
DS                    16 
SWH             6313.131 Hz 
FIDRES          3.082584 Hz 
AQ             0.1622516 sec 
RG                5792.6 
DW                79.200 μsec 
DE                  7.00 μsec 
TE                 300.0 K 
CNST2        145.0000000 
d0            0.00000300 sec 
D1            1.20000005 sec 
d4            0.00172414 sec 
d11           0.03000000 sec 
d13           0.00000400 sec 
D16           0.00020000 sec 
DELTA         0.00172730 sec 
DELTA1       0.00021614 sec 
IN0           0.00001656 sec 
MCREST       0.00000000 sec 
MCWRK         0.00600000 sec 
ST1CNT              50 
 
======== CHANNEL f1 ======== 
NUC1                 1H 
P1                 10.65 μsec 
p2                 21.30 μsec 
P28                 1.00 μsec 
PL1                 0.00 dB 
PL9                54.00 dB 
SFO1         600.2928250 MHz 
======== CHANNEL f2 ======== 
CPDPRG2          garp 
NUC2                 13C 
P3                 13.20 μsec 
p4                 26.40 μsec 
PCPD2              65.00 μsec 
PL2                 0.00 dB 
PL12               13.80 dB 
SFO2         150.9573206 MHz 
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 Parameters for HMBC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
====== GRADIENT CHANNEL ===== 
GPNAM1          SINE.100 
GPNAM2          SINE.100 
GPNAM3          SINE.100 
GPX1                0.00 % 
GPX2                0.00 % 
GPX3                0.00 % 
GPY1                0.00 % 
GPY2                0.00 % 
GPY3                0.00 % 
GPZ1               50.00 % 
GPZ2               30.00 % 
GPZ3               40.10 % 
P16              1000.00 μsec 
 
F1 - Acquisition parameters 
ND0                    2 
TD                    96 
SFO1            150.9573 MHz 
FIDRES        346.068665 Hz 
SW               220.079 ppm 
FnMODE             QF 
 
F2 - Processing parameters 
SI                  2048 
SF           600.2899533 MHz 
WDW                 SINE 
SSB                    0 
LB                  0.00 Hz 
GB                     0 
PC                  1.40 
 
F1 - Processing parameters 
SI                 2048 
MC2                   QF 
SF           150.9426278 MHz 
WDW                 SINE 
SSB                    0 
LB                  0.00 Hz 
GB                     0 
F2 - Acquisition Parameters 
PROBHD    5 mm TXI 1H-13 
PULPROG   hmbcgplpndqfpr 
TD                  2048 
SOLVENT           D2O 
NS                   416 
DS                    16 
SWH             6313.131 Hz 
FIDRES          3.082584 Hz 
AQ             0.1622516 sec 
RG               5792.6 
DW                79.200 μsec 
DE                  7.00 μsec 
TE                 300.0 K 
CNST2        145.0000000 
CNST13         6.0000000 
d0            0.00000300 sec 
D1            1.20000005 sec 
d2            0.00344828 sec 
d6            0.08333334 sec 
D16           0.00020000 sec 
IN0           0.00001505 sec 
MCREST        0.00000000 sec 
MCWRK        0.02000000 sec 
 
======== CHANNEL f1 ======== 
NUC1                 1H 
P1                 10.65 μsec 
p2                 21.30 μsec 
PL1                 0.00 dB 
PL9                54.00 dB 
SFO1         600.2928250 MHz 
 
======== CHANNEL f2 ======== 
NUC2                 13C 
P3                 13.20 usec 
PL2                 0.00 dB 
SFO2         150.9573206 MHz 
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The mean  and median correlation coefficient (together with 95% confidence interval)  for the major acetaminophen metabolites as 1D 
STOCSY ‘driver’ peaks (δ) 
 
  
N-acetyl-cysteine (NAC)  
δ 1.86 
Acetaminophen (A) 
δ 7.25 
Acetaminophen glucuronide 
(AG) 
δ 2.17 
Acetaminophen sulfate (AS) 
δ 7.46 
1.86 1, 1 0.74, 0.74  
(0.62 - 0.84) 
0.61, 0.60  
(0.50 - 0.72) 
0.68, 0.68  
(0.57 - 0.78) 
2.15 0.80, 0.80  
(0.72 - 0.85) 
0.84, 0.84  
(0.71 - 0.92) 
0.82, 0.82  
(0.77 - 0.87) 
0.88, 0.88 
(0.84 - 0.91) 
NAC 
6.96 0.77, 0.77 
(0.71 – 0.82) 
0.73 , 0.74 
(0.60 – 0.83) 
0.63, 0.63 
(0.53 – 0.73) 
0.70, 0.70 
(0.59 – 0.78) 
2.16 0.76, 0.76 
(0.62 - 0.88) 
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(0.71 - 0.90) 
0.87, 0.87 
0.82 - 0.91) 
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(0.63 - 0.76) 
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A 
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Shaded columns indicate the intra-molecular correlation coefficient.  
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